Delivery Order SPE2DR25D1021-SPE2DR26FNN0E
- Not listed
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Procainamide 1 gram/10 mL vials. This competitive, non-set-aside award carries a ceiling value of $3,145.00 and is scheduled for completion by August 12, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Procainamide 1,000 mg/10 mL vials with a ceiling value of $2,897.84 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of October 31, 2025, and represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Procainamide 1 gram/10 mL vials with a ceiling value of $7,465.68. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of November 7, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Procainamide 1 gram/10 milliliter vials with a ceiling value of $3,164.53. This firm fixed-price delivery order, which is not set-aside, is scheduled for completion by August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $2,850.12 by the Defense Logistics Agency's Medical Supply Chain for the procurement of Procainamide 1 gram/10 mL vials. The award, issued on May 29, 2025, with an ultimate completion date of May 30, 2025, utilizes firm fixed pricing with no set-aside designation, indicating the contract was competitively awarded. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Procainamide 1 gram/10 milliliter vials. This competitive award, with a ceiling value of $9,028.89, represents a firm fixed-price delivery order to be completed by September 8, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was used for this procurement. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Procainamide 1,000 mg/10 mL vials with a ceiling value of $9,946.80. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of November 7, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,129.80 for the supply of Procainamide 1,000 mg/10 ml vials on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026....
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Procainamide 1 gram/10 milliliter vials with a ceiling value of $2,505.03. This is a firm fixed price delivery order with an ultimate completion date of July 24, 2025, and represents a non-competitive set-aside contract. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Procainamide 1 gram/10 milliliter vials with a ceiling value of $2,137.63. This is a firm fixed-price delivery order with an ultimate completion date of August 18, 2025, and represents a non-competitive, non-set-aside award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DR25D1021Indefinite Delivery Contract
- SPE2DR25D1021-SPE2DR26FNN0EDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,379.65 to AmerisourceBergen Drug Corp for the supply of Procainamide 1 gram/10 mL vials on November 20, 2025, with completion scheduled for November 21, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's broader pharmaceutical supply vehicle with DLA. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a comprehensive range of pharmaceuticals and medical supplies to support military healthcare systems and other government agencies. The parent IDC serves as a flexible contracting mechanism enabling the delivery of specialty medications, brand-name and generic drugs, and related medical commodities to support Defense Health Agency operations and other federal healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 11/20/25 |